IART has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
IART has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Integra Lifesciences Holdings's Total Stockholders Equity for the quarter that ended in Sep. 2024 was $1,522 Mil. Integra Lifesciences Holdings's Total Assets for the quarter that ended in Sep. 2024 was $4,066 Mil. Therefore, Integra Lifesciences Holdings's Equity to Asset Ratio for the quarter that ended in Sep. 2024 was 0.37.
The historical rank and industry rank for Integra Lifesciences Holdings's Equity-to-Asset or its related term are showing as below:
During the past 13 years, the highest Equity to Asset Ratio of Integra Lifesciences Holdings was 0.46. The lowest was 0.30. And the median was 0.43.
The historical data trend for Integra Lifesciences Holdings's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Integra Lifesciences Holdings Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Equity-to-Asset | Get a 7-Day Free Trial | 0.43 | 0.42 | 0.45 | 0.46 | 0.42 |
Integra Lifesciences Holdings Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Equity-to-Asset | Get a 7-Day Free Trial | 0.42 | 0.42 | 0.39 | 0.38 | 0.37 |
For the Medical Devices subindustry, Integra Lifesciences Holdings's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Integra Lifesciences Holdings's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Integra Lifesciences Holdings's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Integra Lifesciences Holdings's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Equity to Asset (A: Dec. 2023 ) | = | Total Stockholders Equity | / | Total Assets |
= | 1587.884 | / | 3781.988 | |
= | 0.42 |
Integra Lifesciences Holdings's Equity to Asset Ratio for the quarter that ended in Sep. 2024 is calculated as
Equity to Asset (Q: Sep. 2024 ) | = | Total Stockholders Equity | / | Total Assets |
= | 1521.587 | / | 4065.803 | |
= | 0.37 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Integra Lifesciences Holdings (NAS:IART) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Thank you for viewing the detailed overview of Integra Lifesciences Holdings's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Eric Schwartz | officer: Corp VP, Gen Counsel & Sec | C/O ERESEARCHTECHNOLOGY, INC., 1818 MARKET STREET, SUITE 1000, PHILADELPHIA PA 19103 |
Michael J. Mcbreen | officer: Executive VP & President, CSS | 1100 CAMPUS ROAD, PRINCETON NJ 08540 |
Jeffrey Mosebrook | officer: SVP, Fin & PAO | 311 ENTERPRISE DRIVE, PLAINSBORO NJ 08536 |
Stuart Essig | director, officer: President and CEO | 311 C ENTERPRISE DRIVE, PLAINSBORO NJ 08536 |
Barbara B Hill | director | |
Davis Robert T. Jr. | officer: Corp VP, Pres. Neurosurgery | INTEGRA LIFESCIENCES CORPORATION, 311 ENTERPRISE DRIVE, PLAINSBORO NJ 08536 |
Chantal Veillon-berteloot | officer: EVP & CHRO | 1100 CAMPUS ROAD, PRINCETON NJ 08540 |
Lea Daniels Knight | officer: EVP & CFO | 1100 CAMPUS ROAD, PRINCETON NJ 08540 |
Witte Jan De | director, officer: President & CEO | C/O RESMED INC., 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA 92123 |
Harvinder Singh | officer: Exec VP & PRES, International | 1100 CAMPUS ROAD, PRINCETON NJ 08540 |
Lisa Evoli | officer: Chief Human Resources Officer | 311 ENTERPRISE DRIVE, PLAINSBORO NJ 08536 |
Raymond G. Murphy | director | 14604 CARROLTON ROAD, ROCKVILLE MD 20853 |
Renee Wonlai Lo | director | 1100 CAMPUS ROAD, PRINCETON NJ 08540 |
Glenn Coleman | officer: CVP, CHIEF FINANCIAL OFFICER | C/O DENTSLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277 |
Tru St Partnership, L.p. | 10 percent owner | 795 EAST LANCASTER AVE., STE. 200, VILLANOVA PA 19085 |
From GuruFocus
By GuruFocus News • 11-05-2024
By GuruFocus News • 12-04-2024
By GuruFocus News • 11-04-2024
By GuruFocus News • 11-13-2024
By Marketwired • 10-14-2024
By GuruFocus Research • 09-25-2024
By GuruFocus Research • 07-30-2024
By Marketwired • 07-29-2024
By GuruFocus Research • 07-29-2024
By Marketwired • 11-04-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.